Will the credit for future mega-blockbuster drugs, in some cases, go to a carefully-programmed AI discovery system connected to a “self-driving lab” that verified its potential? Certainly, AI is hyped, but so are potential profits of potentially AI-optimized drugs. The exploding volumes of scientific data highlight a shift often overlooked: what does “inventor” even mean when…
PathAI launches AISight digital pathology platform and NSCLC algorithm
PathAI has launched a new digital pathology platform, AISight. Supporting AI-driven research, the digital pathology platform was trained on a real-world dataset of over 5,000 samples with inputs from more than 350,000 cell and tissue-level annotations from more than 50 pathologists. The company has also released its AIM-PD-L1 NSCLC RUO algorithm, which calculates the percentage…